tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Cautious Hold on Kura Oncology Amid Promising Efficacy and Safety Concerns of Ziftomenib
PremiumRatingsCautious Hold on Kura Oncology Amid Promising Efficacy and Safety Concerns of Ziftomenib
1M ago
Promising Clinical Trial Results and Future Prospects Justify Buy Rating for Kura Oncology
Premium
Ratings
Promising Clinical Trial Results and Future Prospects Justify Buy Rating for Kura Oncology
1M ago
Kura Oncology, Kyowa Kirin provide clinical data from KOMET-007
Premium
The Fly
Kura Oncology, Kyowa Kirin provide clinical data from KOMET-007
1M ago
Kura Oncology’s Ziftomenib: Promising Potential in R/R AML Market with Favorable FDA Review and Strategic Growth
PremiumRatingsKura Oncology’s Ziftomenib: Promising Potential in R/R AML Market with Favorable FDA Review and Strategic Growth
2M ago
Kura Oncology’s FDA Priority Review for Ziftomenib
Premium
Company Announcements
Kura Oncology’s FDA Priority Review for Ziftomenib
2M ago
Kura Oncology says ‘positive’ results from KOMET-001 Phase 2 trial of ziftomenib
Premium
The Fly
Kura Oncology says ‘positive’ results from KOMET-001 Phase 2 trial of ziftomenib
2M ago
Kura Oncology price target lowered to $30 from $32 at Mizuho
PremiumThe FlyKura Oncology price target lowered to $30 from $32 at Mizuho
2M ago
Kura Oncology: Promising Clinical Trials and Stable Financials Justify Buy Rating
Premium
Ratings
Kura Oncology: Promising Clinical Trials and Stable Financials Justify Buy Rating
2M ago
Kura, Kyowa say ziftomenib abstract accepted for EHA Congress
Premium
The Fly
Kura, Kyowa say ziftomenib abstract accepted for EHA Congress
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100